Searchable abstracts of presentations at key conferences in endocrinology

ea0024s27 | Endocrine Nurse session | BSPED2010

RCN CYP specialist care forum: endocrine community update

Martin L

Background: 2003 saw the formation of a special interest group within the Royal College of Nursing (RCN) for the growing number of paediatric nurses working within the field of endocrinology. While this group has strong links with the British Society of Paediatric Endocrinology and Diabetes (BSPED) and the British Endocrine Society (BES), it was felt these societies were strongly medical and that a unified voice for paediatric endocrinology nurses would be a useful addition.</...

ea0019s3 | Society for Endocrinology Transatlantic Medal Lecture | SFEBES2009

Estrogen action: two decades of humbling predictions

Jameson L

Over the last two decades, our concepts of estrogen action have changed dramatically. From a clinical perspective, recommendations for estrogen replacement therapy have changed from enthusiasm about the benefits of postmenopausal hormone replacement to recognition that long-term estrogen treatment is associated with increased risk of cardiovascular disease, breast cancer, and uterine cancer. From a basic science perspective, the cloning of the estrogen receptor (ER) provided n...

ea0019p343 | Thyroid | SFEBES2009

Post radioiodine monitoring: do patients feel telephone consultations are an acceptable part of a nurse-led clinic?

Munday L

Rationale for change: Two years ago the Endocrine department instigated an audit of patients who had received radioiodine treatment (RAI) for hyperthyroidism. This highlighted there was a variation in timeliness of follow-up appointments and at least a third of patients were rendered symptomatic as a result of the treatment, prior to review taking place.Innovation: As a result of the initial audit a nurse-led clinic was established to monitor patients fo...

ea0019p359 | Thyroid | SFEBES2009

Audit of the treatment of primary hypothyroidism in a general practice population

Jepson L

Objective: An audit comparing how the treatment of hypothyroidism has changed since the introduction of the Quality Outcome Framework (QOF) in April 2004 according to UK guidelines published by the Association of Clinical Biochemists and the British Thyroid Association (BTA) in 2005.Method: Data were collected from all patients with primary hypothyroidism in a fully computerized practice of 9830 patients under the care of 9 general practitioners. The mos...

ea0015s11 | New twists in appetite/satiety signalling pathways | SFEBES2008

Role of central serotonin 2C receptors in appetite control

Heisler L

The central serotonin (5-hydroxytryptamine, 5-HT) system is an established modulator of ingestive behaviour. Pharmacological and genetic research implicates the serotonin 2C receptor (5-HT2CR) specifically in these effects. New selective 5-HT2CR agonists are being pursued for the treatment of human obesity. We sought to clarify how serotonin in general and the 5-HT2CR in particular modulate ingestive behaviour. The hypothalamus is a key brain r...

ea0011s70 | Endocrine oncogenesis and management of hereditary endocrine tumours | ECE2006

RET function and dysfunction

Fugazzola L

The RET proto-oncogene, located on chromosome 10q11.2 encodes a receptor tyrosine kinase. Its extracellular portion contains four cadherin-like repeats and a cysteine-rich region, while the intracellular portion contains the tyrosine kinase domain. RET is essential for development of the sympathetic, parasympathetic and enteric nervous systems and the kidney. Accordingly, RET disruption by germline mutations causes congenital agangliosis of the gastrointestinal tract (Hirschsp...

ea0009s7 | Symposium 1: Endocrine complications of systemic disorders | BES2005

Parathyroid hormone in children with chronic renal failure

Rees L

There are just over 600 children in the UK on renal replacement therapy, with an annual take-on rate of around 100. There are many more in chronic renal failure (CRF). The main complications are poor growth, renal osteodystrophy and an increased risk of cardiovascular disease in early adulthood, all of which are inter-related.The main player in renal osteodystrophy is hyperparathyroidism, which develops early in the course of CRF. PTH levels can be manip...

ea0007s14 | Pituitary adenomas | BES2004

Somatostatin and dopamine receptors in vitro

Hofland L

The expression of somatostatin (SS) receptors (sst) and dopamine (DA) D2 receptors (D2DR) on pituitary adenomas forms the basis for medical therapy using SS-analogues and DA-agonists. Different types of human pituitary adenomas variably express the five known sst subtypes, as well as D2DR. GH-secreting pituitary adenomas express predominantly sst2 and sst5 mRNA, prolactinomas mainly express sst5 mRNA, while clinically non-functioning pituitary adenomas express sst2 and sst3. I...